Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
212
datasets available to search
ShareScore release 0.9.0
Dataset results
212 results for “5-fluorouracil”
Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C
ClinicalTrials.gov study NCT00346489. IPD Sharing: Not stated. Countries: 1. Publications: 17.
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
ClinicalTrials.gov study NCT03370406. IPD Sharing: YES. Countries: 1. Publications: 13.
Figure 4 from: Al-Ghamdi AH, Mohamed MZ, Elbadry RM, Fouad AA (2024) Kidney protective effect of sitagliptin in 5-fluorouracil-challenged rats. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e114441
Figure 4 H&E (200×) of rat kidneys from: A. control showing normal renal histology; B, C. 5-fluorouracil (5-FU) group demonstrating marked distortion of kidney architecture, renal tubular necrosis and dilatation, desquamation of lining epithelium (black arrows), interstitial edema, areas of coagulative necrosis (white arrow), and inflammatory cell infiltration (black head); D, E. sitagliptin (SIT 5 mg/kg) + 5-FU and (SIT 10 mg/kg) + 5-FU, respectively, showing preservation of the normal kidney architecture; F. tubular injury score. *p < 0.05 vs. control, ≠p < 0.05 vs. 5FU. Results are mean ± S.E.M., n = 8, in each group.
Figure 2 from: Al-Ghamdi AH, Mohamed MZ, Elbadry RM, Fouad AA (2024) Kidney protective effect of sitagliptin in 5-fluorouracil-challenged rats. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e114441
Figure 2 Effects of sitagliptin (SIT) treatment on malondialdehyde (MDA) and total antioxidant capacity (TAC) in kidneys of 5-fluorouracil (5-FU)-challenged rats. *p < 0.05 vs. control, ≠p < 0.05 vs. 5-FU group. Results are mean ± S.E.M, n = 8, in each group.
Figure 3 from: Al-Ghamdi AH, Mohamed MZ, Elbadry RM, Fouad AA (2024) Kidney protective effect of sitagliptin in 5-fluorouracil-challenged rats. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e114441
Figure 3 Effects of sitagliptin (SIT) treatment on: A. Nuclear factor erythroid 2-related factor 2 (Nrf2) and nuclear factor- κB p65 (NF-κB p65); B. Tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β); C. Bax/Bcl-2 ratio and cleaved caspases-3 in kidneys of 5-fluorouracil (5FU)-challenged rats. *p < 0.05 vs. control, ≠p < 0.05 vs. 5-FU group. Results are mean ± S.E.M, n = 8, in each group.
Figure 1 from: Al-Ghamdi AH, Mohamed MZ, Elbadry RM, Fouad AA (2024) Kidney protective effect of sitagliptin in 5-fluorouracil-challenged rats. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e114441
Figure 1 Effects of sitagliptin (SIT) treatment on serum creatinine (Cr) and neutrophil gelatinaseassociated lipocalin (NGAL) of 5-fluorouracil (5-FU)-challenged rats. *p < 0.05 vs. control, ≠p < 0.05 vs. 5-FU group. Results are mean ± S.E.M, n = 8, in each group.
CircRNAs sequencing database of Gastric carcinoma cells (SGC-7901) and 5-fluorouracil-resistant cells (SGC-7901-5-fu)
<p>The circRNAs of two different gastric cancer cell lines were sequenced in this database. The sequencing results were compared and annotated with the database as analysis background data, and the screening conditions for differential expression of circRNA in the two cells line were defined as fold changes (FC) ≥ 2 and P <0.05.</p>
Supplementary material 1 from: Altememy D, Arvejeh PM, Chermahini FA, Alizadeh A, Mazarei M, Khosravian P (2022) A comparative study of combination treatments in metastatic 4t1 cells: everolimus and 5- fluorouracil versus lithium chloride and 5-fluorouracil. Pharmacia 69(3): 755-764. https://doi.org/10.3897/pharmacia.69.e85358
Figures S1–S3
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
ClinicalTrials.gov study NCT00555672. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
ClinicalTrials.gov study NCT05008887. IPD Sharing: NO. Countries: 0. Publications: 11.
5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
ClinicalTrials.gov study NCT02705352. IPD Sharing: NO. Countries: 1. Publications: 0.
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
ClinicalTrials.gov study NCT01525329. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
ClinicalTrials.gov study NCT00009737. IPD Sharing: Not stated. Countries: 14. Publications: 0.
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT04428333. IPD Sharing: YES. Countries: 19. Publications: 0.
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
ClinicalTrials.gov study NCT00417976. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT00983541. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
ClinicalTrials.gov study NCT03861702. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
ClinicalTrials.gov study NCT01671488. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors
ClinicalTrials.gov study NCT02884128. IPD Sharing: NO. Countries: 0. Publications: 1.
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
ClinicalTrials.gov study NCT01286818. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.